Biogen | BIIB - Market Capitalization


Biogen reported $36.5B in Market Capitalization this November of 2026, considering the latest stock price and the number of outstanding shares.





Market Capitalization Change Date
AbbVie USD 508.97B 46.71B Nov/2026
Acadia Pharmaceuticals USD 3.57B 100M Nov/2026
ALKERMES USD 7.43B 629M Nov/2026
Amgen USD 247.94B 20.06B Nov/2026
Bayer EUR 52.42B 5.31B Nov/2026
Biogen USD 33.38B 1.48B Sep/2026
BioMarin Pharmaceutical USD 10.68B 936M Nov/2026
Bristol-Myers Squibb USD 127.46B 9.81B Sep/2026
Eli Lilly USD 1.09T 40.33B Sep/2026
Gilead Sciences USD 184.82B 27.96B Sep/2026
Incyte USD 24.6B 1.95B Sep/2026
Merck USD 375.59B 17.09B Nov/2026
Moderna USD 99.14B 22.26B Nov/2026
Neurocrine Biosciences USD 16.38B 1.96B Nov/2026
Novartis USD 292.09B 51.5B Sep/2026
Pfizer USD 165.12B 1.71B Nov/2026
Sanofi EUR 100.56B 13.53B Nov/2026
Sanofi EUR 114.34B 15.65B Nov/2026
Sarepta Therapeutics USD 1.65B 276M Nov/2026
Teva Pharmaceutical Industries USD 153.58B 106.85B Nov/2026
Ultragenyx Pharmaceutical USD 1.37B 108M Nov/2026
United Therapeutics USD 28.64B 5.4B Nov/2026
Vertex Pharmaceuticals USD 140.44B 7.93B Nov/2026